Target intelligence / Profile preview

HuR-associated fibroblast migratory long noncoding RNA (HAFML)

Target
HAFML
Molecular classification
Long noncoding RNA (lncRNA), Other
01

Overview

HuR-associated fibroblast migratory lncRNA (HAFML) is a long noncoding RNA (lncRNA) located on chromosome 4, implicated in the aggressive behavior of fibroblast-like synoviocytes within rheumatoid arthritis. HAFML is expressed at abnormally high levels in the synovial tissue of RA patients and promotes migration and invasion of FLSs by directly binding to HuR (ELAVL1), a key RNA-binding protein that stabilizes mRNAs. The HAFML–HuR complex enhances the stability and expression of the APPL2 mRNA, which contributes to cellular migration. Knockdown of HAFML or interference with HuR/APPL2 disrupts this pathway, suggesting therapeutic potential for targeting this lncRNA to control synovial aggression and joint destruction in rheumatoid arthritis. HAFML represents a novel molecular target class (lncRNA) distinct from protein-coding targets (e.g., receptors, enzymes) and may offer new therapeutic avenues for diseases characterized by fibroblast dysregulation.

Other names
HuR associated fibroblast migratory lncRNAHuR-associated fibroblast migratory lncRNAENST00000509194
02

Biological functions

Promotes migration and invasion of fibroblast-like synoviocytes (FLS)RNA-protein binding (interacts with HuR/ELAVL1)Stabilization of APPL2 mRNA expressionModulator of cellular phenotype
03

Disease associations

Rheumatoid arthritis (joint destruction via FLS migration and invasion)Potential role in other disorders involving dysregulated fibroblast activity (by analogy to CAFs in cancer) but specifically validated in rheumatoid arthritis

Beyond the preview

Go deeper on HuR-associated fibroblast migratory long noncoding RNA (HAFML).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HuR-associated fibroblast migratory long noncoding RNA (HAFML).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call